The recent creation of the NIH Office of Research Integrity, Validation, and Adoption of New Approach Methodologies (ORIVA) is more than just an administrative shift. It represents a historic inflection point in biomedical research.
For decades, the scientific community has acknowledged the limitations of animal testing: it is expensive, slow, and often poorly predictive of human outcomes. Yet progress toward replacing animal studies with innovative, human-relevant approaches has been incremental, hindered by fragmented standards, a lack of validation pathways, and limited regulatory acceptance.
ORIVA has the potential to change that. By establishing a centralized office dedicated to evaluating, validating, and accelerating new approach methodologies (NAMs), the NIH is signaling that the era of “animals first” is giving way to something far more aligned with human biology and patient needs.
NAMs encompass a diverse set of tools, including organoids, tissue chips, high-throughput screening, and computational models that aim to better replicate human biology than traditional animal models. These technologies have generated enormous enthusiasm, but the barrier has always been validation: How do we know a given NAM is reliable enough to replace or even supplement animal studies in regulatory decision-making?
That’s the problem ORIVA was designed to solve. By prioritizing systematic evaluation, establishing common standards, and creating frameworks for regulatory acceptance, ORIVA provides the infrastructure needed to elevate NAMs from promising experiments to established scientific practice.
The role of computational models in reducing animal use
When we speak about animal testing alternatives, the conversation often centers on cell-based models or engineered tissues. But computational approaches are equally critical, especially when the goal is translation to the clinic. One of the most exciting aspects of ORIVA is its potential to foster cross-sector collaboration. No single approach will replace animal testing overnight; it will take a mosaic of solutions working together. By creating a hub for validation and adoption, ORIVA can help ensure that NAMs are not competing in silos but are integrated into complementary workflows.
Ultimately, ORIVA is not about replacing one research method with another. It’s about building a biomedical ecosystem that delivers safer, more effective therapies to patients, faster and with greater confidence. Every time an investigational drug fails late in the pipeline because preclinical models didn’t predict a safety issue, patients lose years of potential treatment and companies absorb massive costs.
By supporting the rigorous validation of NAMs, ORIVA reduces those risks. Patients can trust that therapies reaching clinical trials have been vetted through methods that reflect human biology, not extrapolations from other species. This strengthens not just science, but public trust, which is a resource that has become increasingly fragile in an era of misinformation.
The establishment of ORIVA is only the beginning. Success will depend on sustained investment, transparent standards, and collaboration between public agencies, private companies, and academic institutions. There will be challenges in harmonizing international guidelines, educating stakeholders, and ensuring that NAMs are accessible beyond elite research hubs.
Human-centered predictions of drug safety and efficacy
At VeriSIM Life, ORIVA resonates deeply with our purpose: to reduce dependence on animal testing and deliver more reliable, human-centered predictions of drug safety and efficacy. Our hybrid AI platform, BIOiSIM(R) creates predictive digital twins of human biology, and ORIVA’s mission is profoundly validating. Our work sits at the intersection of NAM development and validation, using AI-enabled computational simulations to test hypotheses, bridge gaps between in vitro and in vivo data, and provide reproducible evidence that withstands regulatory scrutiny.
ORIVA’s creation means that this bridging function is no longer peripheral; it’s central to the future of research. Our digital twin technology, which can serve as the connective tissue across these efforts, integrating disparate data sources into a cohesive model that reflects human biology with increasing fidelity, integrates diverse data—“omics” profiles, physicochemical properties, mechanistic pathways, and clinical datasets—to create in silico models that predict how a compound will behave in the human body. By doing so, we can answer key questions early: Is this compound likely to be toxic? How will it be metabolized? What patient populations might be most at risk?
This predictive power means fewer compounds need to be pushed into animal studies to “see what happens.” Instead, modeling helps prioritize the safest and most effective candidates, making downstream testing (whether in organoids, tissue chips, or carefully limited animal studies) far more targeted and efficient. In short, computational tools serve as the validation engine that connects novel NAMs with real-world outcomes.
Jo Varshney, PhD, DVM, who pioneered BIOiSIM, is the founder and CEO of VeriSIM Life. Email: [email protected]
